Search Result

Results for "

epz

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (10) CDK (2) Histone Demethylase (1) Histone Methyltransferase (32) MDM-2/p53 (2) Reactive Oxygen Species (ROS) (1) Reference Standards (4) SARS-CoV (2)
By Research Areas:	Cancer (32) Infection (2) Inflammation/Immunology (2) Neurological Disease (1)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13803

Tazemetostat Maximum Cited Publications 89 Publications Verification epz-6438; E-7438	Histone Methyltransferase Apoptosis	Cancer
Tazemetostat (EPZ-6438) is a potent, selective and orally available EZH2 inhibitor. Tazemetostat inhibits the activity of human polycomb repressive complex 2 (PRC2)-containing wild-type EZH2 with a K_i value of 2.5 nM. Tazemetostat inhibits EZH2 with IC₅₀s of 11 and 16 nM in peptide assay and nucleosome assay, respectively. Tazemetostat inhibits rat EZH2 with an IC₅₀ of 4 nM. Tazemetostat also inhibits EZH1 with an IC₅₀ of 392 nM. Tazemetostat induces apoptosis and differentiation specifically in SMARCB1-deleted MRT cells .

HY-15593

Pinometostat 25+ Cited Publications epz-5676	Histone Methyltransferase	Cancer
Pinometostat (EPZ-5676) is a potent DOT1L histone methyltransferase inhibitor with a K_i of 80 pM.

HY-101563

GSK3326595 30+ Cited Publications epz015938	Histone Methyltransferase SARS-CoV MDM-2/p53 CDK Apoptosis	Infection Cancer
GSK3326595 is a protein arginine methyltransferase 5 (PRMT5) inhibitor. GSK3326595 decreases SARS-CoV-2 infection, inhibits cancer cell proliferation and induces pro-inflammatory macrophage polarization and increases hepatic triglyceride levels without affecting atherosclerosis. GSK3326595 can be used for research of relapsed/refractory mantle cell lymphoma .

HY-15227

EPZ004777 5+ Cited Publications	Histone Methyltransferase Apoptosis	Inflammation/Immunology Cancer
EPZ004777 is an effective and selective DOT1L inhibitor, with IC₅₀ being 0.4 nM. EPZ004777 reduces the levels of H3K79me2 and H3K79me1, significantly down-regulating the expression of HOXA9 and MEIS1. EPZ004777 selectively inhibits the proliferation of MLL rearrangement cells and promotes the differentiation and subsequent apoptosis (apoptosis) of leukemia cells. EPZ004777 can be used for the study of leukemia .

HY-12727

EPZ015666 20+ Cited Publications GSK3235025	Histone Methyltransferase	Cancer
EPZ015666 (GSK3235025) is an orally available inhibitor of PRMT5 with an IC₅₀ of 22 nM.

HY-128717A

GSK3368715 dihydrochloride 15+ Cited Publications epz019997 dihydrochloride	Histone Methyltransferase	Cancer
GSK3368715 dihydrochloride (EPZ019997 dihydrochloride) is an orally active, reversible, and S-adenosyl-L-methionine (SAM) uncompetitive type I protein arginine methyltransferases (PRMTs) inhibitor (IC₅₀=3.1 nM (PRMT1), 48 nM (PRMT3), 1148 nM (PRMT4), 5.7 nM (PRMT6), 1.7 nM (PRMT8)). GSK3368715 dihydrochloride (EPZ019997 dihydrochloride) produces a shift in arginine methylation states, alters exon usage, and has strong anti-cancer activity .

HY-100235

GSK591 10+ Cited Publications epz015866; GSK3203591	Histone Methyltransferase	Cancer
GSK591 (EPZ015866), a chemical probe, is a potent and selective inhibitor of protein methyltransferase 5 (PRMT5) with an IC₅₀ of 4 nM .

HY-12970A

EPZ020411 hydrochloride 5+ Cited Publications	Histone Methyltransferase Apoptosis	Cancer
EPZ020411 hydrochloride is a selective inhibitor of PRMT6 with an IC₅₀ of 10 nM, it has >10 folds selectivity for PRMT6 over PRMT1 and PRMT8. EPZ020411 hydrochloride can be used for the research of cancer .

HY-128717

GSK3368715 15+ Cited Publications epz019997	Histone Methyltransferase	Cancer
GSK3368715 (EPZ019997) is an orally active, reversible, and S-adenosyl-L-methionine (SAM) uncompetitive type I protein arginine methyltransferases (PRMTs) inhibitor (IC₅₀=3.1 nM (PRMT1), 48 nM (PRMT3), 1148 nM (PRMT4), 5.7 nM (PRMT6), 1.7 nM (PRMT8)). GSK3368715 (EPZ019997) produces a shift in arginine methylation states, alters exon usage, and has strong anti-cancer activity .

HY-12970

EPZ020411 5+ Cited Publications	Histone Methyltransferase Apoptosis	Cancer
EPZ020411 is a selective inhibitor of PRMT6 with an IC₅₀ of 10 nM, has >10 folds selectivity for PRMT6 over PRMT1 and PRMT8. EPZ020411 can be used for the research of cancer .

HY-19324

EPZ031686 5+ Cited Publications	Histone Methyltransferase	Cancer
EPZ031686 is an potent and orally active SMYD3 inhibitor and with an IC₅₀ value of 3 nM. EPZ031686 can be used for cancer research .

HY-15555

EPZ005687 5 Publications Verification	Histone Methyltransferase	Cancer
EPZ005687 is a potent and selective inhibitor of EZH2 with K_i of 24 nM, and has 50-fold selectivity against EZH1 and 500-fold selectivity against 15 other protein methyltransferases.

HY-13803R

Tazemetostat (Standard) epz-6438 (Standard); E-7438 (Standard)	Reference Standards Histone Methyltransferase Apoptosis	Cancer
Tazemetostat (Standard) is the analytical standard of Tazemetostat. This product is intended for research and analytical applications. Tazemetostat (EPZ-6438) is a potent, selective and orally available EZH2 inhibitor. Tazemetostat inhibits the activity of human polycomb repressive complex 2 (PRC2)-containing wild-type EZH2 with a K_i value of 2.5 nM. Tazemetostat inhibits EZH2 with IC₅₀s of 11 and 16 nM in peptide assay and nucleosome assay, respectively. Tazemetostat inhibits rat EZH2 with an IC₅₀ of 4 nM. Tazemetostat also inhibits EZH1 with an IC₅₀ of 392 nM. Tazemetostat induces apoptosis and differentiation specifically in SMARCB1-deleted MRT cells .

HY-139626

EPZ-719 4 Publications Verification	Histone Methyltransferase	Cancer
EPZ-719 is a selective, orally effective SETD2 inhibitor with an IC₅₀ value of 0.005 μM. EPZ-719 has anticancer activity .

HY-16986

EPZ011989 3 Publications Verification	Histone Methyltransferase	Cancer
EPZ011989 is a potent and orally active Zeste Homolog 2 (EZH2) inhibitor with metabolic stability. EPZ011989 has inhibitory inhibition for EZH2 with a K_i value of <3 nM. EPZ011989 shows robust methyl mark inhibition and anti-tumor activity. EPZ011989 can be used for the research of various cancers . EPZ011989 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-15227A

EPZ004777 hydrochloride 5+ Cited Publications	Histone Methyltransferase Apoptosis	Inflammation/Immunology Cancer
EPZ004777 hydrochloride is an effective and selective DOT1L inhibitor, with IC₅₀ being 0.4 nM. EPZ004777 hydrochloride reduces the levels of H3K79me2 and H3K79me1, significantly down-regulating the expression of HOXA9 and MEIS1. EPZ004777 hydrochloride selectively inhibits the proliferation of MLL rearrangement cells and promotes the differentiation and subsequent apoptosis (apoptosis) of leukemia cells. EPZ004777 hydrochloride can be used for the study of leukemia .

HY-16986B

EPZ011989 hydrochloride 3 Publications Verification	Histone Methyltransferase	Cancer
EPZ011989 hydrochloride is a potent and orally active Zeste Homolog 2 (EZH2) inhibitor, with a K_i value of <3 nM. EPZ011989 shows anti-tumor activity. EPZ011989 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups .

HY-16986A

EPZ011989 trifluoroacetate 3 Publications Verification	Histone Methyltransferase	Cancer
EPZ-011989 trifluoroacetate is a potent and orally active Zeste Homolog 2 (EZH2) inhibitor with metabolic stability. EPZ-011989 trifluoroacetate has inhibitory inhibition for EZH2 with a K_i value of <3 nM. EPZ-011989 trifluoroacetate shows robust methyl mark inhibition and anti-tumor activity. EPZ-011989 trifluoroacetate can be used for the research of various cancers . EPZ011989 (trifluoroacetate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-111589

EPZ-4777	Histone Methyltransferase	Cancer
EPZ-4777 is a selective DOT1L inhibitor which inhibits H3K79 methylation in cancer cells, blocks the expression of leukemogenic genes, and selectively kills cells that contain the translocation. EPZ-4777 can be used for cancer research .

HY-164144

EPZ033294	Histone Methyltransferase	Cancer
EPZ033294 is an inhibitor of SYMD2 (IC₅₀ is 3.9 nM). SYMD2 itself has catalytic activity and can methylate the lysine residue of BTF3 to BTF3me1, which was experimentally demonstrated by detecting an IC₅₀ of 2.9 nM for inhibition of BTF3ME1 by SYMD2, indicating an active inhibition of SYMD2 by EPZ033294. EPZ033294 (0-50 µM) has an inhibitory effect on SYMD2 and a concentration-dependent inhibitory effect in 293T .

HY-117927

EPZ0025654 GSK3536023	Histone Methyltransferase	Cancer
EPZ0025654 (GSK3536023) is an inhibitor for protein arginine methyltransferases 4 (PRMT4) (which is also known as coactivator associated arginine methyltransferase 1 CARM1), with IC₅₀ of 3 nM .

HY-122223

EPZ030456	Histone Methyltransferase	Cancer
EPZ030456 is a potent and selective SMYD3 inhibitor with an IC₅₀ of 48 nM. EPZ030456 can be used for cancer research .

HY-169113

EPZ032597	Histone Methyltransferase	Cancer
EPZ032597 is a selective and noncompetitive SMYD2 inhibitor with an IC₅₀ value of 16 nM. EPZ032597 is promising for research of pancreatic ductal adenocarcinoma .

HY-145444

EPZ028862	Histone Methyltransferase	Cancer
EPZ028862 is a selective SMYD3 inhibitor for cancer research .

HY-15593R

Pinometostat (Standard) epz-5676 (Standard)	Histone Methyltransferase Reference Standards	Cancer
Pinometostat (Standard) is the analytical standard of Pinometostat. This product is intended for research and analytical applications. Pinometostat (EPZ-5676) is a potent DOT1L histone methyltransferase inhibitor with a Ki of 80 pM.

HY-128717B

GSK3368715 trihydrochloride epz019997 trihydrochloride	Histone Methyltransferase	Cancer
GSK3368715 trihydrochloride (EPZ019997) is an orally active, reversible, and S-adenosyl-L-methionine (SAM) uncompetitive type I protein arginine methyltransferases (PRMTs) inhibitor (IC₅₀=3.1 nM (PRMT1), 48 nM (PRMT3), 1148 nM (PRMT4), 5.7 nM (PRMT6), 1.7 nM (PRMT8)). GSK3368715 trihydrochloride (EPZ019997) produces a shift in arginine methylation states, alters exon usage, and has strong anti-cancer activity .

HY-100235A

GSK591 hydrochloride epz015866 hydrochloride; GSK3203591 hydrochloride	Histone Methyltransferase	Cancer
GSK591 (EPZ015866) hydrochloride is a potent and selective inhibitor of protein methyltransferase 5 (PRMT5) with an IC₅₀ of 4 nM .

HY-128717C

GSK3368715 hydrochloride epz019997 hydrochloride	Histone Methyltransferase	Cancer
GSK3368715 (EPZ019997) hydrochloride is an orally active, reversible, SAM-noncompetitive type I protein arginine methyltransferase (PRMT) inhibitor with IC₅₀ values of 3.1 nM (PRMT1), 48 nM (PRMT3), 1148 nM (PRMT4), 5.7 nM (PRMT6), and 1.7 nM (PRMT8). GSK3368715 hydrochloride induces a shift in arginine methylation states, alters exon usage, and exhibits potent anticancer activity .

HY-12970B

EPZ020411 dihydrochloride	Histone Methyltransferase Reactive Oxygen Species (ROS) Apoptosis	Neurological Disease Cancer
EPZ020411 dihydrochloride is a selective, blood-brain barrier-permeable PRMT6 inhibitor with an IC₅₀ of 0.010 μM. EPZ020411 dihydrochloride blocks PRMT6-mediated histone H3R2 methylation, reduces ROS production, and inhibits Apoptosis. EPZ020411 dihydrochloride is applicable to research related to neuropathic pain, colorectal cancer, ototoxicity, hearing loss and glioblastoma .

HY-115619

EPZ004777 formate	Histone Methyltransferase Apoptosis	Cancer
EPZ004777 formate is an effective and selective DOT1L inhibitor, with IC₅₀ being 0.4 nM. EPZ004777 formate reduces the levels of H3K79me2 and H3K79me1, significantly down-regulating the expression of HOXA9 and MEIS1. EPZ004777 formate selectively inhibits the proliferation of MLL rearrangement cells and promotes the differentiation and subsequent apoptosis (apoptosis) of leukemia cells. EPZ004777 formate can be used for the study of leukemia .

HY-183928

EPZ020809	Histone Demethylase	Others
EPZ020809 is a competitive KDM4C inhibitor with a K_i of 31 nM .

HY-100235R

GSK591 (Standard) epz015866 (Standard); GSK3203591 (Standard)	Histone Methyltransferase Reference Standards	Cancer
GSK591 (Standard) is the analytical standard of GSK591 (HY-100235). This product is intended for research and analytical applications. GSK591 (EPZ015866), a chemical probe, is a potent and selective inhibitor of protein methyltransferase 5 (PRMT5) with an IC50 of 4 nM .

HY-101563R

GSK3326595 (Standard) epz015938 (Standard)	Histone Methyltransferase Reference Standards SARS-CoV MDM-2/p53 CDK Apoptosis	Infection Cancer
GSK3326595 (Standard) is the analytical standard of GSK3326595 (HY-101563). This product is intended for research and analytical applications. GSK3326595 is a protein arginine methyltransferase 5 (PRMT5) inhibitor. GSK3326595 decreases SARS-CoV-2 infection, inhibits cancer cell proliferation and induces pro-inflammatory macrophage polarization and increases hepatic triglyceride levels without affecting atherosclerosis. GSK3326595 can be used for research of relapsed/refractory mantle cell lymphoma .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

epz

Inhibitors & Agonists